# Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies

> **NCT03397706** · PHASE1,PHASE2 · COMPLETED · sponsor: **Viracta Therapeutics, Inc.** · enrollment: 64 (actual)

## Conditions studied

- Epstein-Barr Virus-Associated Lymphoma
- Lymphoproliferative Disorders

## Interventions

- **COMBINATION_PRODUCT:** VRx-3996 and valganciclovir

## Key facts

- **NCT ID:** NCT03397706
- **Lead sponsor:** Viracta Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-29
- **Primary completion:** 2023-04-01
- **Final completion:** 2023-05-04
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2025-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03397706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03397706, "Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03397706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*